Cargando…
CAR T Cell Immunotherapy Beyond Haematological Malignancy
Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies. However, their transition beyond haematological malignancy has so far been unsatisfactory. Here, we discuss...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Immunologists
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901698/ https://www.ncbi.nlm.nih.gov/pubmed/35291659 http://dx.doi.org/10.4110/in.2022.22.e6 |